Table 5: Intraocular pressure reduction after adding brimonidine to the medication regimen of patients already using a prostaglandin analogue.

n (patients) Drug Treatment period IOP before brimonidine (mmHg) IOP reduction width (mmHg) IOP reduction rate (%)
Brimonidine 0.2%
Lee DA. J Glaucoma. 2001 [12] 16 Latanoprost 2 months 18.3 5.89 32.2
Reis R. Clin Ther. 2006 [13] 16 Travoprost 4 weeks 17.0 ±3.1 2.3 ± 1.8 13.4 ± 9.1
Brimonidine 0.15%
Konstas AGP. Ophthalmology. 2005 [14] 29 Latanoprost 6 weeks 19.0 ± 1.7 2.2 ± 1.5 11.6
Mundorf T. Adv Ther. 2007 [15] 43 Latanoprost 2 months 21.9 Peak 5.1
Trough 2.0		 23
9
Feldman RM. Ophthalmology. 2007 [16] 79 Travoprost 3 months 21.7 ± 0.33 2.1 ± 0.27 9.7
Brimonidine 0.1%
Day DG. Curr Med Res Opin. 2008 [17] 20 Latanoprost 3 months 19.6 ± 2.94 3.3 ± 2.82 16.8
Araie M. Atarasii Ganka. 2012 [18] 59 PG analogues 52 weeks 18.7 2.7 14.4
Yamamoto C. Atarasii Ganka. 2014 [19] 24 PG analogues 3 months 18.0 ± 2.7 2.1 ± 2.2 11.8 ± 11.4
Hayashi Y. Rinsho Ganka. 2015 [20] 17 PG analogues 12 months 11.5 ± 1.5 1.5 ± 1.3 13.3 ± 10.9
This study (latanoprost or travoprost)
26 PG analogues 12 weeks 15.8 ± 2.3 2.1 ± 2.3 12.1 ± 11.8

Data presented as mean ± standard deviation.
IOP, intraocular pressure; PG, prostaglandin.